Abstract
A young woman with primary pulmonary hypertension developed severe interstitial pneumonia (IP) 5 days after induction of epoprostenol infusion. Although the pathogen involved was not identified, her IP was initially responsive to steroids, and discontinuation of steroid therapy caused the redevelopment of IP. After intensive treatment, including steroid therapy and inhaled nitric oxide, epoprostenol was successfully switched to prostaglandin E1 infusion and she recovered. Epoprostenol infusion can cause a rapid severe IP, even soon after the induction of therapy. Clinicians should keep this syndrome in mind, especially when treating a severe case of IP.
| Original language | English |
|---|---|
| Pages (from-to) | 1205-1207 |
| Number of pages | 3 |
| Journal | Anesthesia and Analgesia |
| Volume | 99 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Oct 1 2004 |
ASJC Scopus subject areas
- Anesthesiology and Pain Medicine
Fingerprint Dive into the research topics of 'Rapid development of severe interstitial pneumonia caused by epoprostenol in a patient with primary pulmonary hypertension'. Together they form a unique fingerprint.
Cite this
Morimatsu, H., Goto, K., Matsusaki, T., Katayama, H., Matsubara, H., Ohe, T., & Morita, K. (2004). Rapid development of severe interstitial pneumonia caused by epoprostenol in a patient with primary pulmonary hypertension. Anesthesia and Analgesia, 99(4), 1205-1207. https://doi.org/10.1213/01.ANE.0000130615.28893.52